Zacks Research Cuts Earnings Estimates for Avanos Medical

Avanos Medical, Inc. (NYSE:AVNS) – Research analysts at Zacks Research cut their Q3 2025 earnings estimates for shares of Avanos Medical in a note issued to investors on Wednesday, November 20th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.41 for the quarter, down from their prior estimate of $0.57. The consensus estimate for Avanos Medical’s current full-year earnings is $1.32 per share. Zacks Research also issued estimates for Avanos Medical’s Q4 2025 earnings at $0.53 EPS and FY2025 earnings at $1.64 EPS.

Separately, StockNews.com downgraded Avanos Medical from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 3rd.

Avanos Medical Price Performance

Shares of Avanos Medical stock opened at $18.60 on Monday. The stock has a market cap of $854.86 million, a price-to-earnings ratio of 54.71 and a beta of 0.92. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.46 and a current ratio of 2.22. The stock has a 50 day moving average price of $21.73 and a 200-day moving average price of $21.54. Avanos Medical has a one year low of $17.39 and a one year high of $25.36.

Hedge Funds Weigh In On Avanos Medical

Hedge funds have recently added to or reduced their stakes in the company. Quarry LP purchased a new position in shares of Avanos Medical during the third quarter valued at approximately $42,000. KBC Group NV lifted its stake in shares of Avanos Medical by 63.0% during the 3rd quarter. KBC Group NV now owns 2,833 shares of the company’s stock worth $68,000 after acquiring an additional 1,095 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in Avanos Medical during the 2nd quarter valued at $70,000. XTX Topco Ltd bought a new position in Avanos Medical in the 2nd quarter valued at $202,000. Finally, Intech Investment Management LLC purchased a new stake in Avanos Medical in the third quarter worth $207,000. 95.17% of the stock is currently owned by institutional investors.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.